Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Han

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 18, 2021
Targeting loss of heterozygosity for cancer-specific immunotherapyMichael S Hwang, Brian J Mog, Jacqueline Douglass, et al.
Biorxiv : the Preprint Server for Biology|December 19, 2025
Engineering immunotoxin-equipped effector cells and evaluation in primary human immune cellsAlexander H Pearlman, Brian J Mog, Michael S Hwang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2026
Lethal toxin-equipped effector cells for the potential treatment of cancerAlexander H Pearlman, Brian J Mog, Michael S Hwang, et al.
Science Translational Medicine|March 2, 2021
TCR β chain-directed bispecific antibodies for the treatment of T cell cancersSuman Paul, Alexander H Pearlman, Jacqueline Douglass, et al.
Nature Communications|August 21, 2023
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigenKatharine M Wright, Sarah R DiNapoli, Michelle S Miller, et al.
Journal for Immunotherapy of Cancer|May 22, 2021
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomesJohn A Ligon, Woonyoung Choi, Gady Cojocaru, et al.
Science Translational Medicine|July 10, 2024
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densitiesBrian J Mog, Nikita Marcou, Sarah R DiNapoli, et al.
Nature Communications|September 7, 2021
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigensMichael S Hwang, Michelle S Miller, Puchong Thirawatananond, et al.
Science (New York, N.Y.)|March 2, 2021
Targeting a neoantigen derived from a common <i>TP53</i> mutationEmily Han-Chung Hsiue, Katharine M Wright, Jacqueline Douglass, et al.
ACS Nano|July 17, 2023
Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain DiseaseRohan Palanki, Sourav K Bose, Apeksha Dave, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|March 18, 2021
Targeting loss of heterozygosity for cancer-specific immunotherapyMichael S Hwang, Brian J Mog, Jacqueline Douglass, et al.
Biorxiv : the Preprint Server for Biology|December 19, 2025
Engineering immunotoxin-equipped effector cells and evaluation in primary human immune cellsAlexander H Pearlman, Brian J Mog, Michael S Hwang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2026
Lethal toxin-equipped effector cells for the potential treatment of cancerAlexander H Pearlman, Brian J Mog, Michael S Hwang, et al.
Science Translational Medicine|March 2, 2021
TCR β chain-directed bispecific antibodies for the treatment of T cell cancersSuman Paul, Alexander H Pearlman, Jacqueline Douglass, et al.
Nature Communications|August 21, 2023
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigenKatharine M Wright, Sarah R DiNapoli, Michelle S Miller, et al.
Journal for Immunotherapy of Cancer|May 22, 2021
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomesJohn A Ligon, Woonyoung Choi, Gady Cojocaru, et al.
Science Translational Medicine|July 10, 2024
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densitiesBrian J Mog, Nikita Marcou, Sarah R DiNapoli, et al.
Nature Communications|September 7, 2021
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigensMichael S Hwang, Michelle S Miller, Puchong Thirawatananond, et al.
Science (New York, N.Y.)|March 2, 2021
Targeting a neoantigen derived from a common <i>TP53</i> mutationEmily Han-Chung Hsiue, Katharine M Wright, Jacqueline Douglass, et al.
ACS Nano|July 17, 2023
Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain DiseaseRohan Palanki, Sourav K Bose, Apeksha Dave, et al.
Pageof 5